Vaccine against tick-borne encephalitis for adults (TicoVac 0.5ml) and children (TicoVac 0.25ml)

Tick-borne encephalitis (TBE) is a serious natural focal viral disease caused by the tick-borne encephalitis virus (TBEV), affecting the brain, its membranes, or peripheral nerves. TBE is one of the most important viral infections of the human central nervous system, characterized by residual effects, sometimes causing disability. TBE is prevalent in many countries worldwide. It was first described in 1927 in Austria, and the causative agent, TBEV, was isolated in 1937 in the former Soviet Union.

According to ULAC data, the mortality rate from TBE is 0.5-4%. About one-third of people who contract TBE do not fully recover. The most common residual effects include difficulty concentrating, sleep disturbances, persistent headaches, increased sensitivity, and behavioral changes. Less frequently, paresis (paralysis) occurs.

The most effective preventive measure against TBE is vaccination. TBE vaccines can be administered to children over 1 year of age. There are two vaccination schedules: regular and accelerated. The first two doses of the regular vaccination schedule are administered at intervals of 1-3 months; the intervals for the third and booster doses may vary depending on the vaccine manufacturer and are specified in the vaccine information leaflet. After full vaccination (3 doses), about 97% of vaccinated individuals develop a protective antibody titer.